Humacyte to Share Third Quarter Financial Results and Updates
Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology company, is set to share its financial results from the quarter that ended on September 30, 2025. This presentation will take place on a Wednesday, November 12, 2025. The event promises to deliver not only the financials but also considerable insights into the company’s corporate progress and future directions.
Live Conference Call and Webcast Details
The management team will be hosting a conference call and webcast at 8:00 a.m. ET. Those interested can join the call using two dedicated numbers: 1-877-704-4453 for U.S. participants and 1-201-389-0920 for international investors. A conference ID will also be required: 13756236. This format is designed to ensure an informative and interactive experience for all investors.
Webcast Access
To enhance accessibility, the webcast will be available 15 minutes before the conference call begins. Following the live discussion, a replay will be accessible on Humacyte's website in the investors section for a minimum of 30 days. This ensures that any investor unable to attend can catch up on the critical information shared during the event.
About Humacyte and Its Revolutionary Technology
Humacyte, Inc. is at the forefront of developing universally implantable, bioengineered human tissues aimed at transforming medical practices and enhancing patient lives. The company’s focus on creating advanced tissue constructs and organ systems is designed to address numerous health challenges, from chronic conditions to severe injuries.
Regulatory Milestones and Innovations
In December 2024, Humacyte achieved a significant milestone when the FDA approved its Biologics License Application for its acellular tissue-engineered vessel (ATEV) targeted toward vascular trauma indications. Furthermore, the ATEV has advanced through late-stage clinical trials for various vascular applications, including critical needs such as arteriovenous (AV) access for hemodialysis. This groundbreaking vessel has not only gained significant recognition but has also achieved Regenerative Medicine Advanced Therapy (RMAT) designation, paving the way for expedited development processes.
Future Developments and Growth Prospects
The company is ambitiously expanding its research frontiers, exploring preclinical development in areas like coronary artery bypass grafts and pediatric cardiac surgeries. Moreover, innovative treatments for type 1 diabetes and various novel cellular and tissue applications are underway, demonstrating Humacyte's commitment to pushing the boundaries of biotechnology.
Investor and Media Relations
For more information or inquiries, investors can reach out to Joyce Allaire at LifeSci Advisors LLC at +1-617-435-6602, or via email at jallaire@lifesciadvisors.com. Meanwhile, for press inquiries, Rich Luchette from Precision Strategies is available at +1-202-845-3924, or by emailing rich@precisionstrategies.com.
Frequently Asked Questions
What is Humacyte’s main focus?
The primary focus of Humacyte is the development of bioengineered human tissues designed for medical use, which aims to improve patient care through innovative solutions.
When will the financial results be announced?
Humacyte will present its financial results for the third quarter of 2025 on November 12, 2025, at 8:00 a.m. ET.
How can I access the conference call?
The conference call can be accessed via dedicated phone lines for U.S. and international investors, along with a specific conference ID required to join.
What significant achievement did Humacyte recently accomplish?
In December 2024, Humacyte received FDA approval for their acellular tissue-engineered vessel (ATEV) for the treatment of vascular trauma, marking a critical regulatory milestone.
How can I stay updated on Humacyte's progress?
Investors and interested parties can visit Humacyte's investor section on their website for updates, including the replay of the webcast following the conference call.
